Biocon and CIM have collaborated for almost a decade on an integrated program to manufacture and clinically evaluate recombinant proteins with the aim of building a portfolio based on therapeutic biotechnology products for chronic diseases.
The collaboration lead to a new monoclonal antibody targeting the Epidermal Growth Factor Receptor for the treatment of cancer, and the human recombinant Erythropoietin, for the control of anemia in chronic kidney diseases, developed under stringent medical regulatory standards, which have already been approved for medical use in India and other territories.
Biocon and CIM have extended the partnership to create a product pipeline focused on autoimmune diseases and cancer.
Fundamental research performed at CIM and Biocon has defined the anti-inflammatory capacity of a new monoclonal antibody, an Anti-CD6 Monoclonal Antibody, which targets lymphocytes.
Biocon chairman and managing director Kiran Mazumdar-Shaw said that the Anti-CD6 targeting antibody has recently transited to advanced clinical trials for the treatment of Psoriasis and Rheumatoid Arthritis patients.
CIM scientist Enrique Montero said that in the long run, it would contribute to the joint development of a scientific program based on Biocon’s and CIM’s complementary capacities.